Summary
The Trade and Cooperation Agreement (TCA) between the UK and the EU was finalized on December 24, 2020, nearly five years after the Brexit referendum of 2016. Even though the TCA guarantees tariff-free trade between both sides, industries will face additional barriers as the EU and the UK will now function as separate legal and regulatory jurisdictions. While the UK’s separation from the EU presents an opportunity for UK’s life-science sector to grow and establish the UK as an innovative regulator, Brexit will continue to generate uncertainty about the prospects of research, manufacturing, funding, regulatory affairs, and trade in the pharmaceutical industry.
In this report, GlobalData examines the business environment, weighs the opportunities, and assesses the risks that the UK’s pharmaceutical industry is going to face post Brexit. The report also highlights the COVID-19 impact on the UK’s economy as major macro events, such as Brexit and the ongoing COVID-19 pandemic, are continuing to affect the UK’s pharmaceutical industry in parallel.
Scope
The research source in this report is based on the opinions and expectations of 150 global healthcare industry professionals surveyed from February 8, 2021, to March 3, 2021 to gauge Brexit impact on the healthcare industry. Components of the report include -
- Outcomes of Brexit: best outcomes of Brexit providing respondent mix by geography as compared to previous survey waves in 2018 and 2019
- Impact on Research and Manufacturing: key factors to impact healthcare research and manufacturing in the UK post-Brexit providing respondent mix by region as compared to previous survey waves in 2018 and 2019
- Factors to Impact Healthcare: key factors to impact the post-Brexit UK healthcare industry providing respondent mix by region as compared to previous survey waves in 2018 and 2019
- Impact on Corporate Strategy: level of impact of Brexit on corporate strategy providing respondent mix by region as compared to previous survey waves in 2018 and 2019
- COVID-19 Impact: COVID-19 impact on the UK’s economy as major macro events, such as Brexit and the ongoing COVID-19 pandemic, are continuing to affect the UK’s pharmaceutical industry in parallel
- Future Prospects: overview of the initiatives that could help the UK’s healthcare sector to recover and emerge strong post-Brexit
Reasons to Buy
- Develop and design your corporate strategies post-Brexit through an in-house expert analysis of the key factors to impact the post-Brexit UK healthcare industry.
- Develop business strategies by understanding the key factors to impact healthcare research and manufacturing in the UK post-Brexit.
- Stay up to date on the industry’s changing sentiment towards Brexit from within the healthcare industry.
- Identify emerging industry trends post-Brexit to gain a competitive advantage.
'
Table of Contents
1 Study Design
1.1 Respondent Mix
1.2 Objectives and Design
1.3 Brexit Timeline
1.4 Respondent Profiles
2 Executive Summary
2.1 Executive Summary
3 UK Pharma Industry and Brexit
3.1 The UK - Real GDP Growth
3.2 The UK Pharma Industry
3.3 Clinical Trial Disruption COVID-19 - A Closer Look
3.4 Change in Brexit Sentiment
3.5 Change in Brexit Sentiment - Respondents’ Perspective
3.6 Brexit and COVID-19 Impact on the UK’s Healthcare Sector
3.7 Emerging Regulatory and Macroeconomic Trends
4 Outcome of Brexit
4.1 The UK-EU Trade and Cooperation Agreement
4.2 Best Outcomes of Brexit
4.3 Best Outcomes of Brexit by Geography
4.4 Best Outcomes of Brexit - Historical Data
4.5 Respondents’ Views on Brexit
5 Impact on Research and Manufacturing
5.1 Brexit’s Impact on Research and Manufacturing
5.2 The UK Pharma Industry Post Brexit
5.3 The UK Pharma Industry Post Brexit - Positives
5.4 The UK Pharma Industry Post Brexit - Negatives
6 Factors to Impact Healthcare
6.1 Factors to Impact the UK’s Healthcare Industry Post Brexit
6.2 Factors to Impact the UK’s Healthcare Industry Post Brexit - Historical Data
6.3 Factors to Impact the UK’s Healthcare Industry Post Brexit by Geography
6.4 The UK-EU Trade and Cooperation Agreement
6.5 Horizon Europe 2020
6.6 The UK-EU Trade and Cooperation Agreement
7 Impact on Corporate Strategy
7.1 Brexit’s Impact on Corporate Strategy
7.2 Brexit’s Impact on Corporate Strategy - 2018 and 2019 Data
7.3 How Has Brexit Most Influenced Corporate Strategy?
7.4 The UK’s Immigration Policy Post Brexit
7.5 UK’s Immigration System - Impact on Healthcare Sector
8 Impact on Corporate Strategy
8.1 COVID-19 Impact on the Outcome of Brexit
8.2 COVID-19 Infection Rates Continue to Rise
8.3 COVID-19 Is a Global Problem
8.4 Country Dealing with COVID-19 Pandemic the Best
8.5 Testing for COVID-19
8.6 The UK Leads Top Economies in Vaccines Administered Per Million Population
8.7 The UK Becomes the First Country to Approve a COVID-19 Vaccine
8.8 COVID-19 Vaccine Availability by Country
8.9 Respondents’ Views on the UK Being the First Country to Approve a COVID-19 Vaccine
9 Future Prospects
9.1 Confidence in the UK’s Pharma Sector Post Brexit
9.2 Initiatives that Could Help the UK’s Healthcare Industry to Recover
9.3 Planned Clinical Trials - 2021
9.4 Medicines and Medical Devices Act 2021
9.5 Project Orbis
10 Summary of Key Findings
10.1 Summary of Key Findings
11 Appendix
11.1 Bibliography
11.2 Authors
11.3 Contributors
12 Contact Us
